Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

Overview of attention for article published in Cell Reports Medicine, March 2025

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

patent: 1 patent

bluesky: 2 Bluesky users

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 712 followers.

RRID:SCR_002798, was just reported to be used in "Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies". RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #methodsmat…

Online now: Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies Online now:

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.